Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three and six months ended June 30, 2019.
We are pleased with our execution and yet another quarter of record results, with strong revenue growth and gross margins, and material progress in our quest to lead today’s biomarker revolution. Our first half and Q2 growth continues to outpace expectations based on stronger adoption momentum and a small level of favorable timing in our consumables business. We believe our growth trajectory in all segments of our business continues to advance productively opposite our longer-term growth target propelled by recent product launches into oncology, expansion of our assay menu, and strong progress in our neurodegeneration portfolio and associated pharma services supporting drug trials and approvals. In addition, we are enthusiastic about our strategic acquisition of UmanDiagnostics, which further accelerates many opportunities for neurofilament light (Nf-L) as a transformative biomarker for neurodegenerative diseases and protects our supply of this important Nf-L antibody. We remain confident in our growth prospects and our ability to pioneer disruption in healthcare.”
Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix
Second quarter 2019 financial highlights
Key financial results for the second quarter of 2019 are shown below:
- Q2 revenue of $13.5M versus prior year Q2 of $8.6M, an increase of 57%.
- Q2 product revenue was $8.8M versus prior year Q2 of $5.2M, an increase of 69%.
- Q2 service and other revenue totaled $4.8M versus prior year Q2 of $3.2M, an increase of 50%.
- Q2 gross margin at 51.2% versus prior year Q2 of 46.0%, an increase of 520 bps
1H 2019 financial highlights
Key financial results for the first half of 2019 are shown below:
- 1H revenue of $25.9M versus prior year 1H of $16.2M, an increase of 60%.
- 1H product revenue was $18.3M versus prior year 1H of $9.9M, an increase of 84%.
- 1H service and other revenue totaled $7.5M versus prior year 1H of $5.7M, an increase of 33%.
- 1H gross margin at 50.0% versus prior year 1H of 44.2%, an increase of 580 bps
Second quarter 2019 business highlights
- Entered into definitive agreement to acquire UmanDiagnostics AB, the world’s leading Nf-L antibody supplier, with the acquisition completed after quarter end. The acquisition allows Quanterix to supply researchers globally with the “best-in-class” Simoa Nf-L assays, while continuing to innovate new digital biomarkers to advance the field of research in diagnostics for neurological disorders. The deal also positions Quanterix to capitalize on the growth fueled by the momentum in Nf-L as a tremendously promising brain biomarker.
- Successfully raised nearly $50 million through an at-the-market equity (ATM) facility, attracting marquee investors, and further enhancing Quanterix’ liquidity and potential for value creation.
- Announced launch of the Simoa HD-X Analyzer, Quanterix’ new, fully automated Simoa bead-based immunoassay instrument model, with commercial shipments beginning in Q4. The HD-X replaces the HD-1 and has been designed to deliver significant productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.
- Completed the move to its expanded headquarters in Billerica, Mass. The 92,000 square-foot state-of-the-art facility allows the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare.
- Took part in major industry presence at the Alzheimer’s Association International Conference (AAIC), the largest and most influential international meeting dedicated to dementia science, where Quanterix presented to partners and customers at a standing-room-only dinner and hosted a panel discussion featuring several of the world’s foremost researchers in Alzheimer’s Disease.
- Received EY’s Entrepreneur Of The Year® 2019 Award in New England recognizing Hrusovsky’s achievements in healthcare technology innovation, Quanterix’ outstanding financial performance, his commitment to powering precision health (PPH) and the founding of the PPH foundation.
- Continued to strengthen its leadership team with the appointment of Amol Chaubal as CFO, John Fry to General Counsel and several key commercial leaders.
- Powered more than 85 percent of the Nf-L biomarker research presented at the American Academy of Neurology’s Annual Meeting. The 36 abstracts used Quanterix’ Simoa technology to validate Nf-L as a potential diagnostic and prognostic biomarker for neurodegeneration.
- Hrusovsky was invited to speak at BIO International Convention, a leading healthcare event featuring world leaders in biotech and pharma, on the company’s vision for continuing to pioneer disruption in healthcare with digital biomarkers.
In conjunction with this announcement, Quanterix Corporation will host a conference call on Aug. 6, 2019, at 10 a.m., EDT to discuss the Company’s financial results and business outlook. To access this call, dial (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 7499384.
A live webcast will be accessible on the Investors section of Quanterix’ website: http://www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call.